Quantcast
Home > Quotes > FTSV

Forty Seven, Inc. Common Stock (FTSV) Quote & Summary Data

FTSV 
$22.93
*  
0.48
2.14%
Get FTSV Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading FTSV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
24
Today's High / Low
$ 23.8335 / $ 21.65
Share Volume
176,400
50 Day Avg. Daily Volume
94,828
Previous Close
$ 22.45
52 Week High / Low
$ 23.13 / $ 12.02
Market Cap
712,311,278
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
176,400
50 Day Avg. Daily Volume:
94,828

Trading Range

The current last sale of $22.93 is 90.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 23.8335 $ 23.13
 Low: $ 21.65 $ 12.02

Company Description (as filed with the SEC)

We are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. We founded Forty Seven based on the insight that blocking CD47, a key signaling molecule that is overexpressed on cancer cells, renders tumors susceptible to macrophages. By harnessing macrophages, we believe that our lead product candidate, 5F9, dosed as a monotherapy or in combination with marketed cancer therapies, can transform the treatment of cancer. 5F9 has demonstrated promising activity in six Phase 1b/2 clinical trials in which we have treated over 190 relapsed or refractory cancer patients with solid or hematologic tumors. We hold worldwide rights to all of our product candidates. We focus our efforts on targeting the CD47 pathway as a way to engage macrophages in fighting tumors.  ... More ...  


Risk Grade

Where does FTSV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 22.02
Open Date:
Dec. 14, 2018
Close Price:
$ 22.93
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info